Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐ WJOG 6210G-Reference-Cited by-同舟云学术

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐ WJOG 6210G

Published:2016-12 Issue:12 Volume:107 Page:1843-1850
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Shitara Kohei¹,Yonesaka Kimio²³,Denda Tadamichi⁴,Yamazaki Kentaro⁵,Moriwaki Toshikazu⁶,Tsuda Masahiro⁷,Takano Toshimi⁸,Okuda Hiroyuki⁹,Nishina Tomohiro¹⁰,Sakai Kazuko¹¹,Nishio Kazuto¹¹,Tokunaga Shoji¹²,Yamanaka Takeharu¹³,Boku Narikazu¹⁴,Hyodo Ichinosuke⁶,Muro Kei¹⁵

Affiliation:

1. Department of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East KashiwaJapan

2. Department of Medical Oncology Kinki University Faculty of Medicine OsakaJapan

3. Department of Medical Oncology Izumi Municipal Hospital OsakaJapan

4. Division of Gastroenterology Chiba Cancer Center ChibaJapan

5. Division of Gastrointestinal Oncology Shizuoka Cancer Center ShizuokaJapan

6. Division of Gastroenterology University of Tsukuba TsukubaJapan

7. Department of Gastroenterological Oncology Hyogo Cancer Center AkashiJapan

8. Department of Medical Oncology Toranomon Hospital TokyoJapan

9. Department of Medical Oncology Keiyukai Sapporo Hospital SapporoJapan

10. Department of Gastrointestinal Medical Oncology National Hospital Organization Shikoku Cancer Center MatsuyamaJapan

11. Department of Genome Biology Kindai University Faculty of Medicine OsakaJapan

12. Medical Information Center Kyushu University Hospital FukuokaJapan

13. Department of Biostatistics Yokohama City University YokohamaJapan

14. Division of Gastrointestinal Medical Oncology National Cancer Center Hospital TokyoJapan

15. Department of Clinical Oncology Aichi Cancer Center Hospital Nagoya Japan

Funder

West Japan Oncology Group (WJOG)

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.13098

Reference26 articles.

1. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz H;N Engl J Med,2014

2. Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

3. Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

4. NCCN.NCCN Clinical Practice Guidelines in Oncology. Colon Cancer. NCCN Practice Guidelines in Oncology version 2. NCCN; USA:2016.

5. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis;BMC Gastroenterology;2024-02-01

2. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study;Clinical Colorectal Cancer;2024-01

3. ARCAD-Asia initiative: leveraging yesterday’s data for tomorrow;ESMO Gastrointestinal Oncology;2023-12

4. BRAF Non-V600 Mutations in Metastatic Colorectal Cancer;Cancers;2023-09-17

5. Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer;Cancers;2023-09-14